The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
What are the novel treatment options for patients with relapsed or refractory WM?
Stephen Ansell
Jorge Castillo
Christian Buske
Monique Minnema
Sheeba Koshy ThomasOn behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on, What are the novel treatment options for patients with relapsed or refractory Waldenstrom's Macroglobulinemia (WM)? This discussion also featured Christian Buske, Monique Minnema, Sheeba Koshy Thomas, and Jorge J. Castillo.
What are the novel treatment options for patients with relapsed or refractory WM?
Buske begins by explaining how chemotherapy-free approaches could be the future of WM treatment and highlights the important role of Bruton’s tyrosine kinase inhibitors. The current structure of clinical trials is discussed, focusing on what patients would want regarding effectiveness, duration of the trial, and limiting exposure to side effects. The panel describes the possible use of immunotherapy vaccines, though these are limited due to burden of disease where they might not be as effective. Finally, Castillo discusses the potential of Bruton’s tyrosine kinase inhibitions, in combination with targeted agents, such as BCL-2 inhibitors, as well as the use of antibody conjugates in the future treatment of WM.
'The International Waldenstrom's Macroglobulinemia Foundation (IWMF) and the Lymphoma Hub are working in collaboration for patients with Waldenstrom's macroglobulinemia. This initiative aims to increase awareness of Waldenstrom's macroglobulinemia among healthcare professionals, patients, caregivers, and the patient advocacy community.
This initiative is funded by Cellectar Biosciences, BeiGene and Eli Lilly. All content is developed independently by SES in collaboration with an expert steering committee; funders are allowed no direct influence on the content of the hub.’
